{"id":966279,"date":"2026-05-21T20:03:14","date_gmt":"2026-05-22T00:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/"},"modified":"2026-05-21T20:03:14","modified_gmt":"2026-05-22T00:03:14","slug":"hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/","title":{"rendered":"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting"},"content":{"rendered":"
\n

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED<\/a>\u201d) (Nasdaq\/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (\u201cASCO\u201d) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.<\/p>\n

Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate (\u201cORR\u201d) per RECIST 1.1, as assessed by the Independent Review Committee (\u201cIRC\u201d). As of the data cut-off of October\u00a08, 2025, the IRC-assessed ORR was 32.3% (95%CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included the IRC-assessed disease control rate (DCR) of 63.1%, median time to response (TTR) of 1.4\u00a0months, median duration of response (DoR) of 9.7 (95%CI: 3.7, 18.5) months, and median progression-free survival (PFS) of 4.0 (95%CI: 2.6, 5.0) months, respectively. The data supported the New Drug Application (NDA) submission to the China National Medical Products Administration (NMPA), which was accepted and granted priority review in December 2025.<\/p>\n

Additionally, further analyses of the fruquintinib\u2019s FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 studies, as well as investigator-initiated studies of fruquintinib and surufatinib spanning across a diverse range of potential tumor indications will be presented.<\/p>\n

Details of the presentations, including links to available abstracts, are as follows:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Abstract title<\/strong>\n <\/td>\n\n Presenter \/ Lead Author<\/strong>\n <\/td>\n\n Presentation details<\/strong>\n <\/td>\n<\/tr>\n
\n SPONSORED STUDIES<\/strong>\n <\/td>\n<\/tr>\n
\n A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas<\/strong>\n <\/td>\nZhi Peng, Beijing, China<\/td>\n4011
Rapid Oral Abstract Session: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary
Monday, June 1, 2026 1:15 PM CDT<\/td>\n<\/tr>\n
\n Tumor shrinkage and depth of response with fruquintinib in patients with metastatic colorectal cancer: Results from FRESCO and FRESCO-2<\/strong>\n <\/td>\nElena Elez, Barcelona, Spain<\/td>\n3555
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal\u00a0<\/td>\n<\/tr>\n
\n Efficacy of fruquintinib plus sintilimab versus axitinib or everolimus by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study<\/strong>\n <\/td>\nKaiwei Yang, Beijing, China<\/td>\n4531
Poster Session: Genitourinary Cancer
\u2013 Kidney and Bladder<\/td>\n<\/tr>\n
\n Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden<\/strong>\n <\/td>\nYuanyuan Qu, Shanghai, China<\/td>\n4533
Poster Session: Genitourinary Cancer
\u2013 Kidney and Bladder<\/td>\n<\/tr>\n
\n Association of Palmar-plantar erythrodysesthesia syndrome (PPES), hypothyroidism and clinical outcome in previously treated endometrial cancer (EMC) with pMMR status: A subgroup analysis of FRUSICA-1<\/strong>\n <\/td>\nXiaotian Han, Shanghai, China<\/td>\ne17612
Publication Only: Gynecologic Cancer<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n INVESTIGATOR-INITIATED STUDIES<\/strong>\n <\/td>\n<\/tr>\n
\n Efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: A prospective, multicenter, randomized controlled trial<\/strong>\n <\/td>\nJianmin Xu, Shanghai, China<\/td>\nLBA3563
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n CONCEPT<\/strong>
\n (combination of cetuximab plus fruquintinib treatment \u00b1<\/strong>
\n immunotherapy): A multicenter, randomized,<\/strong>
\n open-label phase II trial in first-line pMMR RAS\/BRAF wild-type unresectable metastatic colorectal cancer<\/strong>\n <\/td>\n		Yue Liu, Hangzhou, China<\/td>\nTPS3680
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Fruquintinib in combination with tislelizumab vs trifluridine\/tipiracil and bevacizumab in MSS mCRC without active liver metastases: The IKF-080\/QUINTIS trial<\/strong>\n <\/td>\nJoseph Tintelnot, Hamburg, Germany<\/td>\nTPS3684
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n A phase 2 study of fruquintinib combined with sintilimab and chidamide in refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety<\/strong>\n <\/td>\nChang Wang, Changchun, China<\/td>\n2631
Poster Session: Developmental Therapeutics \u2013 Immunotherapy<\/td>\n<\/tr>\n
\n Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with RAS-mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study<\/strong>\n <\/td>\nYun Xu, Shanghai, China<\/td>\n3528
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC)<\/strong>\n <\/td>\nWenhua Li, Shanghai, China<\/td>\n3534
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n A phase II trial of fruquintinib combined with cadonilimab in refractory MSS\/pMMR colorectal cancer with pulmonary metastases<\/strong>\n <\/td>\nMengzhou Guo, Shanghai, China<\/td>\n3552
Poster Session: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric\/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study<\/strong>\n <\/td>\nXiaodong Zhu, Shanghai, China<\/td>\n4063
Poster Session: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Phase II study of utidelone plus fruquintinib for the treatment of platinum-resistant recurrent ovarian cancer (FRUTD trial)<\/strong>\n <\/td>\nHao Wen, Shanghai, China<\/td>\n5579
Poster Session: Gynecologic Cancer<\/td>\n<\/tr>\n
\n Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study<\/strong>\n <\/td>\nWangjun Liao, Guangzhou, China<\/td>\ne15539
Publication Only: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Intermittent fruquintinib plus trifluridine\/tipiracil in refractory metastatic colorectal cancer (mCRC): A single-center, single-arm phase II study<\/strong>\n <\/td>\nYifu He\/Jiayu Niu, Hefei, China<\/td>\ne15560
Publication Only: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Phase I study of liposomal irinotecan plus fruquintinib as third- or later-line therapy for metastatic colorectal cancer<\/strong>\n <\/td>\nQian Li, Nanning, China<\/td>\ne15571
Publication Only: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate\/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial<\/strong>\n <\/td>\nWei Li, Suzhou, China<\/td>\ne15583
Publication Only: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Real-world use of fruquintinib in refractory metastatic colorectal cancer in the United States<\/strong>\n <\/td>\nVasu Bansal, Kansas City, US<\/td>\ne15713
Publication Only: Gastrointestinal Cancer \u2013 Colorectal and Anal<\/td>\n<\/tr>\n
\n Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced gastric\/gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase Ib\/II study (FUNCTION)<\/strong>\n <\/td>\nBeibei Chen, Zhengzhou, China<\/td>\ne16033
Publication Only: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study<\/strong>\n <\/td>\nYanhong Gu, Nanjing, China<\/td>\ne16070
Publication Only: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Updated results of surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma<\/strong>\n <\/td>\nXuetao Shi\/Jingtao Zhong, Jinan, China<\/td>\n4136
Poster Session: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b\/2 trial<\/strong>\n <\/td>\nWenquan Wang, Shanghai, China<\/td>\n4198
Poster Session: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: Update of a prospective single center, single-arm phase II clinical trial<\/strong>\n <\/td>\nHuijuan Yang, Shanghai, China<\/td>\n5586
Poster Session: Gynecologic Cancer<\/td>\n<\/tr>\n
\n Surufatinib for advanced or metastatic chemotherapy-refractory thymic epithelial tumor: A single-arm, single-center, phase II study<\/strong>\n <\/td>\nBei Xu, Shanghai, China<\/td>\n8119
Poster Session: Lung Cancer \u2013 Non-Small Cell Local-Regional\/Small Cell\/Other Thoracic Cancers<\/td>\n<\/tr>\n
\n Surufatinib combined with anti-PD-1\/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study<\/strong>\n <\/td>\nFuxiang Zhou, Wuhan, China<\/td>\ne16172
Publication Only: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Efficacy and safety of surufatinib combined with immune checkpoint inhibitors plus chemotherapy in patients with biliary tract cancers: A real-world study<\/strong>\n <\/td>\nShasha Fan, Changsha, China<\/td>\ne16222
Publication Only: Gastrointestinal Cancer \u2013 Gastroesophageal, Pancreatic, and Hepatobiliary<\/td>\n<\/tr>\n
\n Osimertinib plus savolitinib in osimertinib-resistant non-small-cell lung cancer with low level gene copy number MET: A multi-center, open-label, and phase 2 study<\/strong>\n <\/td>\nXiang Han, Qingdao, China<\/td>\ne20079
Publication Only: Lung Cancer \u2013
Non-Small Cell Local-Regional\/
Small Cell\/Other Thoracic Cancers<\/td>\n<\/tr>\n<\/table>\n

\n
\n
About HUTCHMED<\/strong>\n <\/p>\n

HUTCHMED (Nasdaq\/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com<\/a> or follow us on LinkedIn<\/a>.<\/p>\n

\n
\n Forward-Looking Statements<\/em>
\n <\/strong>\n <\/p>\n

\n This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED\u2019s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, savolitinib and surufatinib, the further clinical development for fruquintinib, savolitinib and surufatinib, its expectations as to whether any studies on fruquintinib, savolitinib and surufatinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study\u2019s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, savolitinib and surufatinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, savolitinib and surufatinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products\u00a0as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED\u2019s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.<\/em>\n <\/p>\n

\n
\n Medical Information<\/em>
\n <\/strong>\n <\/p>\n

\n This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.<\/em>\n <\/p>\n

\n CONTACTS<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Investor Enquiries<\/strong>\n <\/td>\n+852\u00a02121\u00a08200 \/ ir@hutch-med.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Media Enquiries<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
FTI\u00a0Consulting \u2013<\/td>\n+44\u00a020\u00a03727\u00a01030\u00a0\/ HUTCHMED@fticonsulting.com<\/a><\/td>\n<\/tr>\n
Ben Atwell \/ Tim Stamper<\/td>\n+44\u00a07771\u00a0913\u00a0902\u00a0(Mobile)\u00a0\/ +44\u00a07779\u00a0436\u00a0698 (Mobile)<\/td>\n<\/tr>\n
Brunswick \u2013 Zhou Yi<\/td>\n+852\u00a09783\u00a06894\u00a0(Mobile)\u00a0\/ HUTCHMED@brunswickgroup.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Panmure Liberum<\/strong>\n <\/td>\n\n Nominated Advisor and Joint Broker<\/em>\n <\/td>\n<\/tr>\n
Atholl Tweedie\u00a0\/ Emma Earl\u00a0\/ Rupert Dearden<\/td>\n+44\u00a020\u00a07886\u00a02500<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Cavendish<\/strong>\n <\/td>\n\n Joint Broker<\/em>\n <\/td>\n<\/tr>\n
Geoff Nash\u00a0\/ Nigel Birks<\/td>\n+44\u00a020\u00a07220\u00a00500<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Deutsche Numis<\/strong>\n <\/td>\n\n Joint Broker<\/em>\n <\/td>\n<\/tr>\n
Duncan Monteith\u00a0\/ Ramin Naji<\/td>\n+44 20 7545 8000<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (\u201cASCO\u201d) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA. Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate (\u201cORR\u201d) per RECIST 1.1, as assessed by the Independent Review Committee (\u201cIRC\u201d). As of the data cut-off of October\u00a08, 2025, the … <\/p>\n

Continue reading “HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966279","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (\u201cASCO\u201d) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA. Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate (\u201cORR\u201d) per RECIST 1.1, as assessed by the Independent Review Committee (\u201cIRC\u201d). As of the data cut-off of October\u00a08, 2025, the … Continue reading "HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T00:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting\",\"datePublished\":\"2026-05-22T00:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/\"},\"wordCount\":1709,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/\",\"name\":\"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=\",\"datePublished\":\"2026-05-22T00:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - Market Newsdesk","og_description":"HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (\u201cASCO\u201d) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA. Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate (\u201cORR\u201d) per RECIST 1.1, as assessed by the Independent Review Committee (\u201cIRC\u201d). As of the data cut-off of October\u00a08, 2025, the … Continue reading \"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-22T00:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting","datePublished":"2026-05-22T00:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/"},"wordCount":1709,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/","name":"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=","datePublished":"2026-05-22T00:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTExMyM3NjE2MTg3IzIwOTY3MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966279"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}